Anixa Biosciences, Inc. (ANIX)

NASDAQ: ANIX · Delayed Price · USD
2.92
-0.18 (-5.81%)
At close: Jan 27, 2022 4:00 PM
3.23
0.31 (10.62%)
After-hours:Jan 27, 2022 7:54 PM EST
Market Cap87.99M
Revenue (ttm)512,500
Net Income (ttm)-12.95M
Shares Out30.13M
EPS (ttm)-0.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume94,556
Open3.08
Previous Close3.10
Day's Range2.90 - 3.12
52-Week Range2.71 - 8.09
Beta1.67
AnalystsBuy
Price Target11.00 (+276.7%)
Earnings DateJan 27, 2022

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine progr...

IndustryBiotechnology
IPO DateJan 1, 1987
CEOAmit Kumar
Employees4
Stock ExchangeNASDAQ
Ticker SymbolANIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ANIX stock is "Buy" and the 12-month stock price forecast is 11.00.

Price Target
$11.00
(276.71% upside)
Analyst Consensus: Buy

News

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

SAN JOSE, Calif., Jan. 25, 2022 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announce...

2 days ago - PRNewsWire

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious d...

3 days ago - PRNewsWire

Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access E...

SAN JOSE, Calif. , Dec. 16, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announce...

1 month ago - PRNewsWire

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

1 month ago - Zacks Investment Research

Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicro...

SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious dis...

1 month ago - PRNewsWire

Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventati...

SAN JOSE, Calif. and CLEVELAND , Oct. 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious d...

3 months ago - PRNewsWire

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

SAN JOSE, Calif., Oct. 6, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announ...

3 months ago - PRNewsWire

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy

SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announ...

3 months ago - PRNewsWire

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian C...

SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced toda...

4 months ago - PRNewsWire

Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

4 months ago - PRNewsWire

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

4 months ago - PRNewsWire

Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study

The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.

4 months ago - Zacks Investment Research

Anixa Biosciences' CAR-T Therapy To Start Human Trial For Ovarian Cancer

The FDA has signed off Anixa Biosciences Inc's (NASDAQ: ANIX) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, developed in partnership with Moffitt Cancer Center. Anixa Biosciences...

4 months ago - Benzinga

Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T...

SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

4 months ago - PRNewsWire

Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta Variant

Anixa Biosciences Inc (NASDAQ: ANIX) has announced that a genomic variant analysis indicates that its potential compounds may be more effective against the Delta variant than the original wild-type SARS...

5 months ago - Benzinga

Anixa Biosciences' Covid-19 Compounds Expected to be Effective Against the Delta Variant

SAN JOSE, Calif., Aug. 25, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

5 months ago - PRNewsWire

Anixa Biosciences Congratulates Director, Dr. Arnold Baskies for His Appointment to the WHO's Global Breast Cancer In...

SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

5 months ago - PRNewsWire

Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

SAN JOSE, Calif., Aug. 18, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

5 months ago - PRNewsWire

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Clevel...

SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today ...

8 months ago - PRNewsWire

Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application

SAN JOSE, Calif., May 20, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today ...

8 months ago - PRNewsWire

OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug d...

8 months ago - PRNewsWire

Anixa's Stock Craters As FDA Slaps Clinical Hold On CAR-T Program

Anixa Biosciences Inc (NASDAQ: ANIX) shares drop after the FDA has requested additional information on its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Ca...

9 months ago - Benzinga

Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy

SAN JOSE, Calif., April 19, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced toda...

9 months ago - PRNewsWire

Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic

SAN JOSE, Calif., April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

9 months ago - PRNewsWire

Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million

SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infecti...

10 months ago - PRNewsWire